Why Reyvow Is a Big WOW for the Migraine Community!
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Migraine.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Loo, L. S., Ailani, J., Schim, J., Baygani, S., Hundemer, H.-P., Port, M., & Krege, J. H. (2019). Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. The Journal of Headache and Pain, 20(1). doi: 10.1186/s10194-019-1032-x
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211–1259.
- Steiner, T. J., Stovner, L. J., Vos, T., Jensen, R., & Katsarava, Z. (2018, February 21). Migraine is first cause of disability in under 50s: will health politicians now take notice? Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821623/.